Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Seroprevalence of Nmo-Igg Antibody in Neuromyelitis Optica (Nmo) and Its Specificity in Differentiating Nmo From Other Demyelinating Diseases With Overlap Symptoms: An Iranian Experience Pubmed



Harirchian MH1 ; Aghamollaii V1 ; Tafakhori A1 ; Taslimi S1 ; Shahsiah R1 ; Gholipour T2 ; Mohammadi F1 ; Zareshahabady A3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Iranian Center of Neurological Research, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Partners MS Center, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States
  3. 3. Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Iranian Journal of Allergy# Asthma and Immunology Published:2015


Abstract

Neuromyelitis optica is an inflammatory demyelinating disease (IDD) of the CNS, which mainly affects optic nerve and spinal cord. Autoantibodies against aquaporin-4 also known as NMO-IgG have been implicated in the pathogenesis of NMO. We evaluated the sensitivity and specificity of NMO-IgG assay for diagnosing NMO patients and differentiating them from MS patients and those with undifferentiated IDD with overlap symptoms. Eligibility of patients with demyelinating disorders was evaluated based on physical examination, laboratory and imaging studies. Thirty four definite NMO patients (disregarding NMO-IgG status), 34 multiple sclerosis (MS) patients with a history of optic neuritis (ON) or myelitis that were matched for age and disease activity and 44 patients with ON or myelitis attacks fulfilling neither criteria of MS or NMO (NMO spectrum) were selected as undifferentiated group. NMO-IgG was measured in the serum of the included patients by cell-based indirect immunofluorescence assay (IFA). NMO antibody was positive in 11 (32.3%), and 4 (9.09%) patients in NMO and undifferentiated groups, but was undetctable in MS patients. NMO antibody was 32% (95%Cl: 19-49%) sensitive in detecting NMO patients. Its specificity in differentiating NMO from MS subjects was 100 %( 95% Cl: 90-!00%). NMO antibody was 95% (95% Cl: 0.88-0.98) specific in differentiating NMOs from other demyelinating diseases. Our results showed that although NMO antibody is highly specific for NMO, current method of measuring it with cell-based IFA is not highly sensitive for diagnosing NMO patients. Copyright © Winter 2015.
Related Docs
View other Related Docs
1. Diagnosis and Management of Neuromyelitis Optica Spectrum Disorder (Nmosd) in Iran: A Consensus Guideline and Recommendations, Multiple Sclerosis and Related Disorders (2017)
2. The Possible Role of Interleukin-6 As a Regulator of Insulin Sensitivity in Patients With Neuromyelitis Optica Spectrum Disorder, BMC Neurology (2021)
3. The Role of Cerebellar Abnormalities in Neuromyelitis Optica - a Comparison With Multiple Sclerosis and Healthy Controls, Multiple Sclerosis (2015)
4. A Comparison of Pediatric and Adult Neuromyelitis Optica Spectrum Disorders: A Review of Clinical Manifestation, Diagnosis, and Treatment, Journal of the Neurological Sciences (2018)
5. Polymorphism of the Dna Repair Gene Xdp Increases the Risk of Systemic Lupus Erythematosus But Not Multiple Sclerosis in the Iranian Population, Multiple Sclerosis and Related Disorders (2021)
6. Association of Nod-Like Receptor Protein-3 Single Nucleotide Gene Polymorphisms and Expression With the Susceptibility to Relapsing–Remitting Multiple Sclerosis, International Journal of Immunogenetics (2018)
7. Circumpapillary Retinal Nerve Fiber Layer, Optic Nerve Head, and Related Structural Abnormalities, Atlas of Ocular Optical Coherence Tomograph# Second Edition (2023)
8. Multiple Sclerosis Influences on the Augmentation of Serum Klotho Concentration, Journal of the Neurological Sciences (2016)
Experts (# of related papers)
View all Related Experts
Mohammad Ali Sahraian (9)
Abdolreaza Naser Moghadasi (6)
Other Related Docs
9. The Role of the Il-33/St2 Immune Pathway in Autoimmunity: New Insights and Perspectives, Immunological Investigations (2022)
10. Clinical Characteristics and Disability Progression of Early-And Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis, Journal of Clinical Medicine (2020)
11. Environmental and Genetic Risk Factors in the Development of Neuromyelitis Optica, Expert Review of Ophthalmology (2020)
12. Interaction Between the Protective Effects of Cannabidiol and Palmitoylethanolamide in Experimental Model of Multiple Sclerosis in C57bl/6 Mice, Neuroscience (2015)
13. Aquaporins and Diseases Pathogenesis: From Trivial to Undeniable Involvements, a Disease-Based Point of View, Journal of Cellular Physiology (2021)
14. Efficacy and Safety of Rituximab in Patients With Refractory Neuromyelitis Optica Spectrum Disorders: A Prospective Observation in Iranian Cases, Caspian Journal of Internal Medicine (2020)
15. Role of Microbiota-Derived Short-Chain Fatty Acids in Nervous System Disorders, Biomedicine and Pharmacotherapy (2021)
16. Classification Algorithms With Multi-Modal Data Fusion Could Accurately Distinguish Neuromyelitis Optica From Multiple Sclerosis, NeuroImage: Clinical (2015)
17. Neuromyelitis Optica With Linear Enhancement of Corpus Callosum in Brain Magnetic Resonance Imaging With Contrast: A Case Report, Journal of Medical Case Reports (2015)
18. Consensus Recommendations for the Diagnosis and Treatment of Multiple Sclerosis: 2019 Revisions to the Menactrims Guidelines, Multiple Sclerosis and Related Disorders (2020)
19. Multiple Sclerosis: Clinical Features, Pathophysiology, Diagnosis, and Management, Neuroinflammation (2018)